Ultragenyx Pharmaceutical reported $330.82M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Insmed USD 403.69M 42.4M Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Kyowa Hakko Kirin JPY 92.94B 20.17B Sep/2025
MacroGenics USD 67M 8M Sep/2025
Moderna USD 1.28B 232M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025